Financial Performance - The company's operating revenue for the first half of 2024 was ¥740,012,638.31, a decrease of 45.84% compared to ¥1,366,320,775.95 in the same period last year[14]. - The net profit attributable to shareholders of the listed company was -¥230,490,246.48, representing a decline of 147.54% from ¥484,800,243.90 in the previous year[14]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥13,297,925.77, down 102.77% from ¥479,908,924.21 in the same period last year[14]. - The net cash flow from operating activities was ¥128,224,217.42, a decrease of 60.21% compared to ¥322,265,158.20 in the previous year[14]. - The total profit for the same period was -298.33 million yuan, down 152.87% compared to the previous year[37]. - The company faced significant revenue loss of approximately 554.31 million yuan due to price reductions from insulin centralized procurement[37]. - The company reported a net loss of CNY 44,151,749.21 for the first half of 2024, compared to a profit of CNY 562,500,365.85 in the same period of 2023[127]. - The total comprehensive income for the period was a loss of CNY 230,528,192.68, reflecting challenges in the market[139]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,044,136,810.76, a decrease of 9.36% from ¥7,771,366,505.90 at the end of the previous year[14]. - The company's equity attributable to shareholders decreased to ¥6,490,820,999.36 from ¥7,211,198,787.69, a decline of approximately 10.0%[122]. - The company's cash and cash equivalents decreased by 56.77% to approximately CNY 477.40 million, primarily due to a reduction in operating income and increased external investments[58]. - The total liabilities decreased slightly to ¥548,268,026.17 from ¥555,081,986.78, a reduction of about 1.5%[122]. - The company's long-term equity investments increased by 30.34% to approximately CNY 519.81 million, mainly due to the addition of a new joint venture investment in Junhe Alliance[58]. Research and Development - The company focuses on diabetes and endocrine drug development, with a product line that includes various insulin formulations and related medical devices[20]. - The company is developing two GLP-1 class innovative drugs, targeting both glycemic control and weight loss, to meet the rising demand in the diabetes treatment market[27]. - The company has established a comprehensive R&D, procurement, production, and sales model focused on diabetes and endocrine treatment products[24]. - The company plans to increase R&D investment and optimize its R&D pipeline to expand treatment areas[37]. - Research and development expenses increased to CNY 47,139,587.42 from CNY 44,775,018.62, an increase of 7.9%[127]. Market Position and Strategy - The company is positioned as a leading enterprise in the domestic diabetes treatment sector, focusing on expanding its product offerings and market presence[20]. - The company successfully won A-class selection for its entire insulin product line in the national insulin procurement, accelerating nationwide access and volume[28]. - Since May 2022, the company has optimized sales strategies and expanded market share despite price reductions due to national insulin procurement policies, achieving a 90% to 100% procurement demand for its products[25]. - The company aims to provide integrated solutions for diabetes treatment through a complete insulin delivery system and patient management services[20]. - The company is expanding its international market presence, with the human insulin injection application accepted by the European Medicines Agency (EMA) and GMP inspection passed in July 2024[50][51]. Environmental and Regulatory Compliance - The company invested over 7 million RMB in environmental protection measures in the first half of 2024, focusing on wastewater treatment and hazardous waste disposal[85]. - The company’s emissions of COD and ammonia nitrogen were 26.13 mg/L and 0.34 mg/L respectively, both below the permitted levels of 80 mg/L and 10 mg/L[78]. - The company has implemented VOCs treatment facilities for its production base, which operated normally in the first half of 2024[80]. - The company’s pollution discharge permit is valid from March 7, 2023, to March 6, 2028, with quarterly and annual reports submitted as required[77]. - The company’s wastewater treatment capacity has been upgraded from 1,000 tons/day to 2,000 tons/hour, with 24-hour online monitoring implemented[85]. Corporate Governance and Management - The company held its first extraordinary general meeting on February 27, 2024, where it approved eight resolutions, including adjustments to the repurchase of shares and termination of the 2020 stock incentive plan[67]. - The company appointed Li Jiahong as the chairman of the board on March 27, 2024, following the resignation of the previous chairman[70]. - The company is expanding its management system and internal controls to adapt to its rapid growth and operational challenges[66]. - The company has not disclosed any new product developments or market expansion strategies in the current report[66]. - The company has not reported any changes in the controlling shareholder or actual controller during the reporting period[116]. Shareholder Information - The total number of ordinary shareholders reached 99,367 by the end of the reporting period[111]. - The largest shareholder, Dongbao Industrial Group, holds 591,699,387 shares, representing 29.86% of the total shares[113]. - The company plans to repurchase shares worth between 40 million to 60 million RMB, with the chairman already having increased his holdings by 5,279,900 shares, or 0.27% of total shares[116]. - The total number of shares held by the top ten unrestricted shareholders includes significant holdings from various investment funds[115]. - The company has not issued any preferred shares or convertible bonds during the reporting period[117][118].

证券代码：600867 证券简称：通化东宝 公告编号：2024-078 通化东宝药业股份有限公司 关于 2024 年第二期以集中竞价交易方式 回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 回购股份金额：不低于人民币 18,000 万元（含），不超过人民币 20,000 万 元（含）； ● 回购股份价格：不超过人民币 12 元/股（含）；该回购股份价格上限不高于 董事会审议通过本次回购股份方案前 30 个交易日公司股票交易均价的 150%； ● 回购股份方式：公司通过上海证券交易所交易系统以集中竞价交易的方式 进行股份回购； ● 回购股份期限：自股东大会审议通过本次回购股份方案之日起 6 个月内； ● 相关股东是否存在减持计划：公司副总经理陈红先生因个人资金需求，自 2024 年 6 月 3 日至 2024 年 9 月 2 日（窗口期内不减持），通过集中竞价方式减持 合计不超过 70,000 股,减持比例占公司总股本的 0.0035%，减持比例占陈红先生个 人持有股份的 24.0678 ...

证券代码：600867 证券简称：通化东宝 公告编号：2024-076 通化东宝药业股份有限公司 1 关于GLP-1/GIP双靶点受体激动剂（注射用THDBH120） 减重适应症Ib期临床试验完成首例受试者给药的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 通化东宝药业股份有限公司（以下简称"公司"）全资子公司东宝紫星（杭州） 生物医药有限公司（以下简称"东宝紫星"）取得国家药品监督管理局药品审评中 心（CDE）签发的关于注射用THDBH120减重适应症药物临床试验批准通知书后， 已开展Ib期临床试验，现就相关情况公告如下： 一、药物基本情况 9. 药物临床试验批准：国家药品监督管理局核准签发药物临床试验批准通知书 （2024LP00990；2024LP00991；2024LP00992），同意开展临床试验。 二、研发投入 截至本公告日，公司在该项目中研发投入人民币约6,640.34万元。 三、药物情况及进展 注射用 THDBH120（减重适应症）在获得国家药品监督管理局的药物临床试验 批准后，根据国内化学药品创新药相 ...

证券代码：600867 证券简称：通化东宝 公告编号：2024-070 通化东宝药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 通化东宝药业股份有限公司（以下简称"公司"、"通化东宝"）于 2024 年 7 月 8 日召开第十一届董事会第八次会议，审议通过了《关于以集中竞价交易 方式回购公司股份方案的议案》。具体内容详见 2024 年 7 月 9 日在中国证券报、 上海证券报和上海证券交易所网站（www.sse.com.cn）披露的《通化东宝关于以 集中竞价交易方式回购公司股份方案的公告》（公告编号：2024-061）、《通化 东宝关于以集中竞价交易方式回购公司股份的回购报告书》（公告编号： 2024-062）。 根据《上市公司股份回购规则》、《上海证券交易所上市公司自律监管指引 第 7 号—回购股份》等有关规定,现将公司董事会公告回购股份决议的前一个交 易日（2024 年 7 月 8 日）登记在册的前十大股东和前十大无限售条件股东的名 称及持股数量、比例情况公告如下: | 序号 | 股东名称 | 持股数量（ ...

证券代码：600867 证券简称：通化东宝 公告编号：2024-065 通化东宝药业股份有限公司 关于 2024 年第二期以集中竞价交易方式 回购公司股份方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 回购股份金额：不低于人民币 18,000 万元（含），不超过人民币 20,000 万 元（含）； ● 回购股份价格：不超过人民币 12 元/股（含）；该回购股份价格上限不高于 董事会审议通过本次回购股份方案前 30 个交易日公司股票交易均价的 150%； ● 回购股份方式：公司拟通过上海证券交易所交易系统以集中竞价交易的方 式进行股份回购。 ● 回购股份期限：自股东大会审议通过本次回购股份方案之日起 6 个月内； ● 相关股东是否存在减持计划：公司副总经理陈红先生因个人资金需求，自 2024 年 6 月 3 日至 2024 年 9 月 2 日（窗口期内不减持），通过集中竞价方式减持 合计不超过 70,000 股,减持比例占公司总股本的 0.0035%，减持比例占陈红先生个 人持有股份的 24.06 ...

Financial Performance - The company expects a net profit of -223.91 million CNY for the first half of 2024, a decrease of 708.71 million CNY compared to the same period last year[1] - The net profit after deducting non-recurring gains and losses is projected to be -8.01 million CNY, down 48.79 million CNY year-on-year[1] - Revenue for the first half of 2024 is estimated at approximately 756.06 million CNY, a decrease of 44.66% compared to the previous year[3] Revenue Decline Factors - The decline in revenue is primarily due to a new round of insulin centralized procurement leading to price reductions, which is expected to decrease revenue by about 538 million CNY[3] - The company will incur a one-time write-off or refund of inventory products due to price differences, reducing revenue by approximately 72 million CNY and net profit by about 61.20 million CNY after tax effects[3] Project Termination Impact - The company has decided to terminate the clinical development of the THDB0207 injection project, resulting in a total impairment of 64.56 million CNY and a loss of 253.52 million CNY related to prepayments[4] - The termination of the project is expected to reduce the net profit for the first half of 2024 by 270.37 million CNY and decrease non-recurring gains and losses by 215.50 million CNY[4] - The company will need to allocate additional development expenses of 50 to 70 million CNY if the project were to continue, which is no longer feasible[4] Market Competition - The company faces increased competition from similar insulin products that are already on the market or will be launched soon, which may pressure product pricing[4] Financial Reporting - The financial data provided is preliminary and subject to final confirmation in the official half-year report[6]

Financial Performance - The company's operating revenue for Q1 2024 was ¥591,386,056.41, representing a decrease of 11.12% compared to the same period last year[4]. - The net profit attributable to shareholders for Q1 2024 was ¥214,676,914.76, down 14.28% year-over-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥215,055,971.86, a decrease of 13.01% compared to the previous year[4]. - Basic earnings per share for Q1 2024 were ¥0.11, down 15.38% from the same period last year[5]. - The total operating profit for Q1 2024 was CNY 238.86 million, down from CNY 289.61 million in the same period last year, representing a decline of 17.6%[20]. - The total comprehensive income attributable to the parent company for Q1 2024 was CNY 214.68 million, down from CNY 250.44 million in Q1 2023, a decrease of 14.3%[21]. Cash Flow and Assets - The net cash flow from operating activities was ¥153,275,829.45, reflecting a slight decrease of 1.99% year-over-year[4]. - Cash and cash equivalents as of March 31, 2024, were CNY 1,073,276,217.81, a slight decrease from CNY 1,104,204,462.65 at the end of 2023[16]. - The company has maintained a stable cash position with total current assets rising to CNY 2,879,291,563.65 from CNY 2,816,354,808.02[16]. - The company reported a decrease in cash and cash equivalents at the end of Q1 2024 to CNY 1,073.28 million from CNY 858.22 million at the end of Q1 2023, a decrease of 20.5%[23]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 87,302[8]. - The total number of shares held by Dongbao Industrial Group Co., Ltd. is 591,699,387, accounting for 29.68% of the total shares[9]. - Tianjin Zhenyi Equity Investment Partnership holds 183,058,967 shares, representing 9.18% of the total shares[9]. - The top ten shareholders include Hong Kong Central Clearing Limited with 54,498,972 shares (2.73%) and Abu Dhabi Investment Authority with 36,391,629 shares (1.83%)[9]. - The company has not identified any other related party relationships among shareholders or whether they are acting in concert[9]. Operational Insights - The report does not indicate any significant changes in the operational situation during the reporting period[14]. - The company has not reported any new important information regarding its operational situation during the reporting period[14]. - The company continues to focus on market expansion and product development as part of its strategic initiatives for future growth[19]. Costs and Expenses - Total operating costs for Q1 2024 were CNY 376,188,158.32, down from CNY 394,621,559.44 in Q1 2023, reflecting a cost reduction strategy[19]. - R&D expenses for Q1 2024 amounted to CNY 27,016,540.93, slightly decreased from CNY 27,828,681.61 in Q1 2023, indicating continued investment in innovation[19]. Investment Performance - Investment income for Q1 2024 was CNY 20,241,972.78, an increase from CNY 14,096,658.33 in Q1 2023, showing improved performance in investment activities[19].

Financial Performance - The net profit attributable to the parent company for 2023 is CNY 1,167,835,317.79, with undistributed profits amounting to CNY 3,697,417,176.64[6]. - The proposed cash dividend is CNY 2.50 per 10 shares, totaling CNY 495,433,518.50 (including tax), which represents 42.42% of the net profit attributable to shareholders[7]. - The remaining undistributed profits after the dividend distribution will be CNY 3,201,983,658.14, to be carried forward for future distribution[7]. - The company's operating revenue for 2023 was approximately ¥3.08 billion, representing a year-over-year increase of 10.69% compared to ¥2.78 billion in 2022[25]. - Net profit attributable to shareholders decreased by 26.17% to approximately ¥1.17 billion in 2023 from ¥1.58 billion in 2022[25]. - The basic earnings per share for 2023 was ¥0.59, down 25.32% from ¥0.79 in 2022[26]. - The weighted average return on equity decreased to 17.09%, a decline of 7.43 percentage points from 24.52% in 2022[27]. - The total assets increased by 15.13% to approximately ¥7.77 billion at the end of 2023, compared to ¥6.75 billion at the end of 2022[25]. - Cash flow from operating activities was approximately ¥861.52 million, a slight decrease of 0.18% from ¥863.09 million in 2022[25]. - The total net assets attributable to shareholders increased by 10.19% to approximately ¥7.21 billion at the end of 2023 from ¥6.54 billion at the end of 2022[25]. - The total profit for 2023 was 1,365.90 million CNY, a decrease of 25.34% compared to the previous year[84]. - The net profit after deducting non-recurring gains and losses increased by 38.88% to 1,167.51 million CNY[84]. Market and Product Performance - Insulin product sales increased significantly, with insulin analog products achieving over 60% growth in sales volume during the reporting period[34]. - The company signed a strategic cooperation agreement for insulin injection liquids in the U.S. market, contributing to revenue growth[35]. - The company maintained a market share of over 40% in human insulin, ranking first in the industry, while insulin analogs saw a market share growth of nearly 10%[39]. - Total sales volume of insulin products reached 83.22 million units, a year-on-year increase of 12.84%[39]. - The company is expanding its treatment areas beyond diabetes to include gout and hyperuricemia, with ongoing research projects for new drugs[40]. - The company has made progress in developing innovative drugs targeting multiple mechanisms for diabetes treatment, including SGLT1/SGLT2/DPP4 inhibitors[41]. - The company has successfully launched GLP-1RA liraglutide injection and oral hypoglycemic agent empagliflozin, covering a comprehensive range of diabetes treatment products[47]. - The company is advancing its international strategy, with human insulin injection application accepted by the European Medicines Agency in H1 2023 and strategic cooperation established for entering the U.S. insulin market[51]. - The company is focusing on the development of innovative drugs and high-value generics, responding to market pressures and regulatory changes[138]. Research and Development - The company has established R&D institutions in multiple cities, focusing on new drug development and international registration[76]. - The company is actively developing two innovative GLP-1 drugs, with the first phase of clinical trials for both candidates already initiated[68]. - The company has ongoing projects for GLP-1 receptor agonists and SGLT1/SGLT2/DPP4 inhibitors, currently in Phase I clinical trials[118]. - The company reported R&D investment of 420.42 million RMB, an increase of 4.74% compared to the previous year[124]. - The company has a significant pipeline of new products, including various insulin analogs and GLP-1 receptor agonists, with total R&D expenditures reaching 12,679.87 RMB million for the rapid-acting insulin analog[126]. - The company emphasizes innovation as a key strategy to enhance core competitiveness in a stabilizing market[124]. Governance and Compliance - The company held one annual and one temporary shareholders' meeting during the reporting period, ensuring compliance with legal requirements and protecting shareholder rights[151]. - The board of directors consists of 9 members, including 3 independent directors, and has held 7 meetings to ensure sound governance practices[151]. - The company has established specialized committees under the board, including the audit committee, strategy committee, nomination committee, and compensation and assessment committee[176]. - The company has not faced any penalties from securities regulatory authorities in the past three years[172]. - The company has established a comprehensive internal control system to improve risk management and operational standards in response to expanding business operations[153]. Employee and Management Structure - The total number of employees in the parent company is 3,164, with 1,361 in sales and 617 in technical roles[186]. - The company has implemented a training program to enhance employee skills, focusing on various areas including quality control and risk management[188]. - The company has established a comprehensive salary policy based on employee qualifications and company performance[187]. - The company has maintained stable leadership with no significant turnover among its senior management team[158]. - The company has appointed new senior management personnel, including a general manager and board secretary, during the recent board meetings[172]. Risk Management - There are no significant risks that materially affect the company's operations during the reporting period[12]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[9]. - The company faced significant industry policy risks due to increased regulatory scrutiny in the pharmaceutical sector, particularly following the national centralized procurement of insulin products, which led to price reductions starting in May 2022[147]. - The company has streamlined operations and enhanced management practices to mitigate the impact of price declines, aiming to increase market share outside of centralized procurement[147].

证券代码：600867 证券简称：通化东宝 编号：2023-079 通化东宝药业股份有限公司 关于口服小分子GLP-1受体激动剂（THDBH110胶囊） I期临床试验完成首例受试者入组的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 通化东宝药业股份有限公司（以下简称"公司"）全资子公司东宝紫星（杭州） 生物医药有限公司（以下简称"东宝紫星"）收到国家药品监督管理局药品审评中 心签发的关于口服小分子GLP-1受体激动剂（THDBH110胶囊）药物临床试验批准通 知书 后，已经启动Ⅰ期临床试验，并于近日完成首例受试者入组。现将相关情况公 告如下： 一、药物基本情况 1. 药物名称：THDBH110胶囊 2. 剂型：胶囊剂 3. 规格：5mg、20mg、60mg 4. 注册分类：化学药品1类 5. 申请人：东宝紫星（杭州）生物医药有限公司 THDBH110胶囊后的药代动力学特征、药效动力学特征。试验目前进展顺利，已于 近日成功完成首例受试者入组。 四、其它情况说明 胰高血糖素样肽-1（GLP-1）受体是当前治疗II型糖尿病最受 ...

关于利拉鲁肽注射液获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 通化东宝药业股份有限公司（以下简称"公司"或"通化东宝"）于近日收到 国家药品监督管理局核准签发的利拉鲁肽注射液《药品注册证书》，现对相关信息 公告如下： 一、药物基本情况 1、药物名称：利拉鲁肽注射液 二、审查结论 证券代码：600867 证券简称：通化东宝 编号：2023-078 通化东宝药业股份有限公司 根据《中华人民共和国药品管理法》及有关规定，经审查，利拉鲁肽注射液符合 药品注册的有关要求，批准注册，发给药品注册证书。 三、研发投入 截至本公告日，公司在该相关研发项目已累计投入人民币约23,997万元。 四、药品的其他情况说明 利拉鲁肽是一种人胰高血糖素样肽-1（GLP-1）类似物，可激活人GLP-1受体， 促进胰腺分泌胰岛素。该品种由诺和诺德公司（NOVO NORDISK）研制，于2011年进 1 2、商品名称：统博力 3、剂型：注射剂 4、申请事项：药品注册（境内生产） 5、规格：3ml:18mg（预填充） 6、注册分类：治 ...